medigraphic.com
ISSN 1561-302X (Print)

2014, Number 1

<< Back Next >>

Rev cubana med 2014; 53 (1)

Markers of thrombosis in patient with thrombophilia

Castañeda TM, Carballo TTI, Gómez LM, Torres YW, Cepero LK, González HO

Language: Spanish
References: 24
Page: 14-24
PDF size: 80.73 Kb.


ABSTRACT

Introduction: thrombophilia is a clinical condition characterized by an excessive tendency to arterial or venous thromboembolism due to diverse reasons, included genetic and acquired causes, as well as their interactions. It produces high morbidity and mortality.
Objective: to characterize the behavior of thrombogenesis markers in patients diagnosed with thrombophilia, to determine the association of these with the occurrence of thrombotic complications and to determine the association between genetic markers and genetic-acquired recurrence of these complications.
Method: 107 patients fromed the sample (males and females, ages younger than 45). They were assisted in the thrombophilia consultation at Hermanos Ameijeiras Hospital, from February 2011 to September 2012. As part of the thrombophilic profile, antithrombin (AT), proteins C and S (PC, PS), and lupus anticoagulant (LA) were assessed by chromogenic and coagulometric studies. The genetic disorders such as Factor V Leiden (FVL) and and Factor II G20210 A (PG20210A) were studied by polymerase chain reaction.
Results: a prevalence of white race was seen for developing thrombotic events, with a higher number of patients with thrombogenic markers and combinations for this ethnic group (x2=19.52 and a p=0.001). Both genders had equal probability to develop thrombotic events (x2=0.512 and a p=0.4750). The appearance of vein occlusive events and their recurrence was more frequent in the studied patients (x2=59.16 and a p=0.000 and an x2=8.7 and a p=0.003 respectively) and this frequency increased, when associated to acquired risks (x2=18.13 and a p=0.000). The prevalent genetic marker in patients with thrombosis was FLV x2=16.2 and a p=0.000 for an OR=11.9; IC=2.72-52.5.
Conclusions: these results are very important in predicting the recurrence of thrombotic events so as to take the prophylactic and therapeutic measures needed in patients with thrombophilia.


REFERENCES

  1. Virchow RLK. Cellular pathology as based upon physiological and pathohistology. American. 1860;(7):236-40.

  2. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J HaematoL. 2008;143(2):18090.

  3. Torres IW, Colina RA. Trombofilias. En: Suardíaz JH, Cruz CL, Colina RA. Laboratorio Clínico. La Habana: Editorial Ciencias Médicas. 2004;30:349-61.

  4. Izaguirre-AR. A un siglo de la teoría clásica de la coagulación sanguínea. Haematologica. 2006;29(2):116-23.

  5. Kordich LC. Concepto actual del sistema de coagulación. Invest Clin. 2009;50(Sup.2):35-8.

  6. Agutter PS. The Aetiology of Deep Venous Thrombosis: A Critical, Historical and Epistemological Survey. Berlin: Springer; 2008:84-6.

  7. Lane DA, Mannucci PM, Bauer KA, Bertina R et al. Inherited thrombophilia. part. 1. Thromb Haemost. 1996;76:651-2.

  8. Majluf-CM, ALarrañaga EF. Fisiopatología de la trombosis. Gac Méd Méx. 2007;143(Supl1):11-14.

  9. Soria JM, Fontcuberta J. New approaches and future prospects for evaluating genetic risk of thrombosis. Haematologica. 2005;90:212-22.

  10. Rosendaal FR. Risk factors for venous thrombosis: genes and lifestyle. Haematologica (edición española). 2009;94:242-4.

  11. Ageno W, Dentali F. Venous thromboembolism and arterial thromboembolis. Many similarities, far beyond thrombosis per se. Thromb Haemost. 2008;100:181-3.

  12. Stéffano de PB. Fundamento de los métodos usados para la evaluación en el laboratorio de Hemostasia. Invest Clin. 2009;50(sup 2):38- 40.

  13. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism: a meta-analysis involving ~120,000 cases and 180,000 controls. Thromb Haemost. 2009;102:360-70.

  14. Torres YW. Trombofilia hereditaria en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2009;25(sup):89-112.

  15. Nieto AJ, Ruiz RMD Tromboembolia pulmonar. Luces y sombras. Rev Esp Cardiol. 2008;61:229-32.

  16. Albánez S. Frecuencia de ocho polimorfismos protrombóticos en pacientes con trombosis venosa profunda. Un estudio caso-control en Venezuela. Investigación Clinica. 2009;50(Sup 2):135-37.

  17. Mahmoodi BK, Brouwer JL, Veeger NJ. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation. 2008 14;118(16):1659-67.

  18. Lim W. Antiphospholipid antibody syndrome. Hematology. 2009;25(10):2333-9.

  19. Christiansen SC, Cannegieter SC, Koster T. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352-61.

  20. Franchini M, Mannucci PM. Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med. 2008;19:476-81.

  21. Agredo DK. Caracterización y manejo del paciente con sospecha de trombosis venosa profunda en una clínica de segundo nivel de Popayán, Cauca. Facultad Popayán. Colombia: Ciencias de la Salud, Universidad del Cauca; 2007:1-8.

  22. Corral J, Roldán V, Vicente V. Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica. 2010;95(6):863-6.

  23. Bezemer ID, van der Meer FJ, Eikenboom JC. The value of family history as a risk indicator for venous. Arch Intern Med. 2010; 169:610-5.

  24. Crim MT. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):2472-85.




2020     |     www.medigraphic.com